Martin D. Abel

Assessment of Diastolic Function of the Heart: Background and Current Applications of Doppler Echocardiography. Part II. Clinical Studies

Evaluation of diastolic filling of the heart has been difficult because of its complexity and the numerous interrelated contributing factors. Previous determinations have depended on high-fidelity, invasive measurements of instantaneous pressure, volume, mass, and wall stress, which could not be done on a routine clinical basis. With the advent of Doppler echocardiography, intracardiac blood flow velocities can now be noninvasively assessed. For application of this technique to evaluation of diastolic function in patients with heart disease, it is necessary to understand what the Doppler-derived variables represent. It is also necessary to know how they are affected by changes in loading conditions and changes in myocardial relaxation. In this review, we provide an interpretation of the mitral valve, tricuspid valve, and systemic and pulmonary venous inflow velocities in the normal patient and in various disease states.

Transesophageal Echocardiography: Technique, Anatomic Correlations, Implementation, and Clinical Applications

The introduction of transesophageal echocardiography has provided a new acoustic window to the heart and mediastinum. High-quality images of certain cardiovascular structures [left atrial appendage, thoracic aorta, mitral valvular apparatus, and atrial septum] can be obtained readily (average examination, 15 to 20 minutes). In this article, we discuss the technique of image acquisition, image orientation, and anatomic validation. In addition, we describe our experience with the first 100 awake patients who underwent transesophageal echocardiography at our institution. The procedure was well accepted by the patients and associated with no major complications. The clinical indications for this procedure have included thoracic aortic dissection, prosthetic cardiac valve dysfunction, detection of an intracardiac source of embolism, endocarditis, cardiac and paracardiac masses, and mitral regurgitation. Transesophageal echocardiography also proved to be useful in assessment of critically ill patients in whom standard transthoracic echocardiographic images did not provide complete assessment. In these patients (who had extensive chest trauma, had undergone an operation, or were in an intensive-care unit), rapid assessment of the cardiovascular status at the bedside was possible with transesophageal echocardiography. On the basis of our initial experience, we conclude that transesophageal echocardiography complements standard two-dimensional Doppler and color flow examinations and will considerably improve the care of patients with cardiovascular disorders by providing high-quality unique images.

Relation of pulmonary vein to mitral flow velocities by transesophageal Doppler echocardiography. Effect of different loading conditions.

It has previously been demonstrated that predictable changes occur in mitral flow velocities under different loading conditions. The purpose of this study was to relate changes in pulmonary venous and mitral flow velocities during different loading conditions as assessed by transesophageal echocardiography in the operating room. Nineteen patients had measurements of hemodynamics, that is, mitral and pulmonary vein flow velocities during the control situation, a decrease in preload by administration of nitroglycerin, an increase in preload by administration of fluids, and an increase in afterload by infusion of phenylephrine. There was a direct correlation between the changes in the mitral E velocity and the early peak diastolic velocity in the pulmonary vein curves (r = 0.61) as well as a direct correlation between the deceleration time of the mitral and pulmonary venous flow velocities in early diastole (r = 0.84). This indicates that diastolic flow velocity in the pulmonary vein is determined by the same factors that influence the mitral flow velocity curves. A decrease in preload caused a significant reduction in the initial E velocity and prolongation of deceleration time, and an increase in preload caused an increase in E velocity and shortening of deceleration time. An increase in afterload produced a variable effect on the initial E velocity and deceleration time and was dependent on the left ventricular filling pressure. The change in systolic forward flow velocity in the pulmonary vein was directly proportional to the change in cardiac output (r = 0.60). The pulmonary capillary wedge pressure correlated best with the flow velocity reversal in the pulmonary vein at atrial contraction (r = 0.81). Use of pulmonary vein velocities in conjunction with mitral flow velocities can help in understanding left ventricular filling.

Intensive Intraoperative Insulin Therapy versus Conventional Glucose Management during Cardiac Surgery: A Randomized Trial

Context Intensive insulin therapy used to maintain normoglycemia during intensive care after cardiac surgery improves perioperative outcomes. Its effect during cardiac surgery is unknown. Contributions The authors randomly assigned 400 cardiac surgical patients to tight glycemic control (blood glucose level, 4.4 to 5.6 mmol/L [80 to 100 mg/dL]) during surgery or usual intraoperative care. All patients received tight glycemic control in the cardiac intensive care unit. The groups had the same risk for perioperative adverse events (risk ratio, 1.0 [95% CI, 0.8 to 1.2]). The intensive treatment group had more strokes (8 vs. 1) and more deaths (4 vs. 0) than the conventional treatment group. Caution The authors performed the study at a single center. Implications Maintaining normoglycemia during cardiac surgery does not improve outcomes and might worsen them. The Editors Hyperglycemia occurs frequently in patients with and without diabetes during cardiac surgery, especially during cardiopulmonary bypass surgery (1, 2). In a study by Van den Berghe and colleagues (3), intensive insulin therapy after surgery reduced morbidity and death in critically ill patients, most of whom underwent cardiac surgery. As a result, professional organizations have recommended rigorous glycemic control in hospitalized patients (4) and strict glycemic control is now routine practice during the postoperative period in cardiac surgical patients. However, no consensus exists on the optimal management of intraoperative hyperglycemia in cardiac surgical patients because of the lack of evidence from randomized trials. Researchers are increasingly extrapolating evidence from studies that assess the role of strict postoperative glycemic control in critically ill patients to advocate for intravenous insulin therapy for patients in the operating room (3, 57). Evidence, strictly from observational studies, suggests that tight intraoperative glycemic control may reduce postoperative complications (810). We recently reported, in a retrospective, observational study of 409 cardiac surgical patients, that intraoperative hyperglycemia was an independent risk factor for perioperative complications, including death, after adjustment for postoperative glucose concentrations. Each 1.1-mmol/L (20 mg/dL) increase in glucose concentration greater than 5.6 mmol/L (>100 mg/dL) during surgery was associated with a 34% increase in the likelihood of postoperative complications (8). An association between intraoperative hyperglycemia and adverse outcomes based on observational studies does not prove causality. Because hyperglycemia can adversely affect immunity, wound healing, and vascular function, the concept that normoglycemia be maintained during the relatively brief duration of cardiac surgery seems plausible (1116). On the other hand, the degree of intraoperative hyperglycemia may merely reflect the severity of underlying stress. If so, prevention of hyperglycemia might not reduce perioperative complications, and the risks and costs of intensive intraoperative glycemic management may outweigh the benefits. Simple, safe, and effective insulin infusion algorithms that achieve rigorous intraoperative glycemic control are lacking. To address these questions, we conducted a randomized, controlled trial at 1 center to determine whether maintenance of near normoglycemia during cardiac surgery by using intraoperative intravenous insulin infusion reduced perioperative death and morbidity when added to rigorous postoperative glycemic control. Methods Design Overview This was a randomized, open-label, controlled trial with blinded assessment. We randomly assigned patients to receive intensive insulin therapy to maintain intraoperative glucose levels between 4.4 (80 mg/dL) and 5.6 mmol/L (100 mg/dL) or conventional treatment. By design, both groups were postoperatively treated with strict glycemic control to ensure that the observed difference in outcome could be attributed to the effects of intraoperative glycemic control. Setting We performed the study at St. Marys Hospital, Rochester, Minnesota, which is a tertiary care teaching hospital with 1157 beds and an average of more than 41000 admissions per year. Participants Adults undergoing elective cardiac surgery between July 2004 and April 2005 were eligible for enrollment in our study. We excluded patients who had off-pump cardiopulmonary bypass procedures. The Mayo Foundation Institutional Review Board, Rochester, Minnesota, approved the protocol. Randomization and Interventions Before we enrolled patients in our randomized trial, we enrolled 20 patients in a 2-week pilot trial to ensure that the anesthesiologists in the operating room and the nursing staff in the intensive care units (ICUs) had adequate experience with the study insulin infusion algorithm. The 20 patients received intensive insulin therapy during surgery and for 24 hours after surgery. The pilot period data allowed us to modify the graded insulin infusion to achieve desired glucose concentration goals. We built safety features into our infusion protocol to minimize hypoglycemia. We discontinued the infusion when glucose levels were less than 4.4 mmol/L (<80 mg/dL) and initiated dextrose infusion. When glucose levels decreased to less than 3.3 mmol/L (<60 mg/dL), we treated hypoglycemia according to a standardized hypoglycemia protocol. Per protocol, patients treated in the pilot phase were not included in the analyzed cohort. Study coordinators obtained written informed consent from all patients who met eligibility criteria. We randomly assigned patients to receive intensive or conventional intraoperative insulin therapy. Randomization was computer-generated with permuted blocks of 4, with stratification according to surgeon, surgical procedure (coronary artery bypass grafting [CABG] with or without other procedures and no CABG), and diabetes. The randomization assignments were concealed in opaque, sealed, tamper-proof envelopes that were opened sequentially by study personnel after participants signed the patient consent form. We could not possibly know, before obtaining consent, the few patients who would not have intraoperative hyperglycemia (glucose concentration of 5.6 mmol/L or more [100 mg/dL]). Therefore, per protocol, patients who gave consent were randomly assigned, and those whose glucose levels were less than 5.6 mmol/L (<100 mg/dL) during surgery were not included in the final analyses. Intraoperative Period Intensive Treatment Patients in the intensive treatment group received a continuous intravenous insulin infusion, 250 units of NovoLin R (Novo Nordisk, Princeton, New Jersey) in 250 mL of 0.45% sodium chloride, when their blood glucose levels exceeded 5.6 mmol/L (>100 mg/dL). We adjusted the infusions to maintain blood glucose levels between 4.4 (80 mg/dL) and 5.6 mmol/L (100 mg/dL). We adjusted the dose according to a standardized algorithm used by anesthesiologists (Appendix Table 1). Appendix Table 1. Insulin Infusion Protocol* Conventional Treatment Patients in the conventional treatment group did not receive insulin during surgery unless their glucose levels exceeded 11.1 mmol/L (200 mg/dL). If glucose concentration was between 11.1 (200 mg/dL) and 13.9 mmol/L (250 mg/dL), patients received an intravenous bolus of 4 units insulin every hour until the glucose concentration was less than 11.1 mmol/L (<200 mg/dL). If the intraoperative glucose concentration was greater than 13.9 mmol/L (>250 mg/dL), patients received an intravenous infusion of insulin that was continued until the glucose level was less than 8.3 mmol/L (<150 mg/dL). In both study groups, we measured arterial plasma glucose concentration every 30 minutes, starting just before anesthetic induction by using hexokinase method on a Double P Modular System (Roche Diagnostics, Indianapolis, Indiana). Intraoperative procedures, including cardiopulmonary bypass, monitoring, laboratory testing, and treatment, were left to the discretion of anesthesiologists and cardiac surgeons. There was no standard protocol for monitoring and managing intraoperative potassium levels. Postoperative Period Intravenous insulin infusion was started in patients in the conventional treatment group on their arrival in the ICU. Thereafter, both study groups were treated identically, with the intravenous insulin infusion rates adjusted by a nursing staff that was not involved with the study according to a standard protocol. The target blood glucose range was 4.4 (80 mg/dL) to 5.6 mmol/L (100 mg/dL) (Appendix Table 1). Arterial blood glucose levels were measured every 1 to 2 hours by using the Accu-Check Inform blood glucose monitoring system (glucometer) (Roche Diagnostics). During the first 24 hours after surgery, patients were given only clear liquids by mouth; we did not administer subcutaneous insulin or oral diabetic medications during this time. Thereafter, the hospital diabetes consulting service saw all patients and provided individualized recommendations for ongoing care. Outcomes and Measurements The primary outcome variable was a composite of death, sternal wound infections, prolonged pulmonary ventilation, cardiac arrhythmias (new-onset atrial fibrillation, heart block requiring permanent pacemaker, or cardiac arrest), stroke, and acute renal failure within 30 days after surgery. Secondary outcome measures were length of stay in the ICU and hospital. Trained study personnel identified the occurrence of a complication through chart abstraction by using confirmable, objective criteria in accordance with standardized definitions from the Society of Thoracic Surgeons (STS) database committee (17). Personnel who assessed outcomes were not aware of patient treatment assignment or of the study hypothesis. Follow-up Procedures We contacted patients by telephone and used a standardized telephone survey at 30 days after surgery to assess outcomes that occurred after discharge. We considered pat

Practice guidelines for perioperative transesophageal echocardiography

P RACTICE Guidelines are systematically developed recommendations that assist the practitioner and the patient in making decisions about health care. These recommendations may be adopted, modified, or rejected according to clinical needs and constraints and are not intended to replace local institutional policies. In addition, Practice Guidelines developed by the American Society of Anesthesiologists (ASA) are not intended as standards or absolute requirements, and their use cannot guarantee any specific outcome. Practice Guidelines are subject to revision as warranted by the evolution of medical knowledge, technology, and practice. They provide basic recommendations that are supported by a synthesis and analysis of the current literature, expert and practitioner opinion, open forum commentary, and clinical feasibility data. This update includes data published since the Practice Guidelines for Perioperative Transesophageal Echocardiography were adopted by the ASA and the Society of Cardiovascular Anesthesiologists in 1995 and published in 1996. Methodology

Intraoperative Hyperglycemia and Perioperative Outcomes in Cardiac Surgery Patients

OBJECTIVE To estimate the magnitude of association between intraoperative hyperglycemia and perioperative outcomes in patients who underwent cardiac surgery. PATIENTS AND METHODS We conducted a retrospective observational study of consecutive adult patients who underwent cardiac surgery between June 10, 2002, and August 30, 2002, at the Mayo Clinic, a tertiary care center in Rochester, Minn. The primary independent variable was the mean intraoperative glucose concentration. The primary end point was a composite of death and infectious (sternal wound, urinary tract, sepsis), neurologic (stroke, coma, delirium), renal (acute renal failure), cardiac (new-onset atrial fibrillation, heart block, cardiac arrest), and pulmonary (prolonged pulmonary ventilation, pneumonia) complications developing within 30 days after cardiac surgery. RESULTS Among 409 patients who underwent cardiac surgery, those experiencing a primary end point were more likely to be male and older, have diabetes mellitus, undergo coronary artery bypass grafting, and receive insulin during surgery (P< or =.05 for all comparisons). Atrial fibrillation (n=105), prolonged pulmonary ventilation (n=53), delirium (n=22), and urinary tract infection (n=16) were the most common complications. The initial, mean, and maximal intraoperative glucose concentrations were significantly higher in patients experiencing the primary end point (P<.01 for all comparisons). In multivariable analyses, mean and maximal glucose levels remained significantly associated with outcomes after adjusting for potentially confounding variables, including postoperative glucose concentration. Logistic regression analyses indicated that a 20-mg/dL increase in the mean intraoperative glucose level was associated with an increase of more than 30% in outcomes (adjusted odds ratio, 1.34; 95% confidence Interval, 1.10-1.62). CONCLUSION Intraoperative hyperglycemia is an independent risk factor for complications, including death, after cardiac surgery.

Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study.

OBJECTIVES The objective was to determine the independent association between atrial fibrillation (A-Fib) and activation of natriuretic peptides. BACKGROUND The association of A-Fib with activation of N-terminal atrial and brain natriuretic peptides (N-ANPs and BNPs, respectively) is uncertain but of great importance for the diagnostic utilization of natriuretic peptides. This uncertainty is related to the lack of appropriate controls, with left ventricular (LV) and atrial overload similar to A-Fib. METHODS We prospectively measured N-terminal atrial and BNPs and endothelin-1 levels in 100 patients and 14 age- and gender-matched control subjects. The 32 patients with A-Fib were compared with 68 patients in sinus rhythm and similar LV and atrial overload (due to mitral regurgitation or LV dysfunction) measured simultaneously with hormonal levels with comprehensive Doppler echocardiography. RESULTS Patients with A-Fib compared with those in sinus rhythm had similar symptoms, comorbid conditions, cardioactive medications, pulmonary pressure, left atrial volume, and LV ejection fraction and filling characteristics but demonstrated higher N-ANP levels (2,613 +/- 1,681 vs. 1,654 +/- 1,323 pg/ml, p = 0.007) even after adjustment for the underlying cardiac disease (p < 0.0001). Conversely, BNP levels were similar in both groups (165 +/- 163 vs. 160 +/- 269 pg/ml, p = 0.9). In multivariate analysis, a higher N-ANP level was associated with A-Fib (p = 0.0003), symptom class (p < 0.0001) and endothelin-1 level (p = 0.032) independently of left atrial volume and LV ejection fraction. Conversely, BNP showed no independent association with and was most strongly associated with LV ejection fraction (p < 0.0001). CONCLUSIONS Atrial fibrillation is an independent determinant of higher N-ANP levels and blurs its association with LV dysfunction. Conversely, the BNP is not independently associated with A-Fib and is strongly determined by LV dysfunction, for which it is an independent marker.

Real-Time Three-Dimensional Transesophageal Echocardiography in the Intraoperative Assessment of Mitral Valve Disease

BACKGROUND The aims of this study were to evaluate the feasibility of real-time 3-dimensional (3D) transesophageal echocardiography in the intraoperative assessment of mitral valve (MV) pathology and to compare this novel technique with 2-dimensional (2D) transesophageal echocardiography. METHODS Forty-two consecutive patients undergoing MV repair for mitral regurgitation (MR) were studied prospectively. Intraoperative 2D and 3D transesophageal echocardiographic (TEE) examinations were performed using a recently introduced TEE probe that provides real-time 3D imaging. Expert echocardiographers blinded to 2D TEE findings assessed the etiology of MR on 3D transesophageal echocardiography. Similarly, experts blinded to 3D TEE findings assessed 2D TEE findings. Both were compared with the anatomic findings reported by the surgeon. RESULTS At the time of surgical inspection, ischemic MR was identified in 12% of patients, complex bileaflet myxomatous disease in 31%, and specific scallop disease in 55%. Three-dimensional TEE image acquisition was performed in a short period of time (60 +/- 18 seconds) and was feasible in all patients, with optimal (36%) or good (33%) imaging quality in the majority of cases. Three-dimensional TEE imaging was superior to 2D TEE imaging in the diagnosis of P1, A2, A3, and bileaflet disease (P < .05). CONCLUSIONS Real-time 3D transesophageal echocardiography is a feasible method for identifying specific MV pathology in the setting of complex disease and can be expeditiously used in the intraoperative evaluation of patients undergoing MV repair.

Intraoperative Transesophageal Echocardiography: 5-Year Prospective Review of Impact on Surgical Management

OBJECTIVE To determine the impact of intraoperative transesophageal echocardiography (IOTEE), an important adjunct in many types of cardiac surgical cases, on the surgical decisions made perioperatively in adult patients undergoing cardiac surgery. PATIENTS AND METHODS All adult patients who had cardiac surgery between 1993 and 1997 and who also had IOTEE were studied. New findings before and after cardiopulmonary bypass and alterations in the planned surgical procedure or management were documented prospectively. RESULTS A total of 3245 patients (60% men, 40% women; aged 18-93 years with a mean +/- SD age of 62 +/- 15 years) were included in the study. The most common operations performed were mitral valve repair (26%) and aortic valve replacement (22%). Over the 5-year period, 41% of patients had IOTEE. New information was found before bypass in 15% of patients, directly affecting surgery in 14% of the patients. The most common new prebypass information found was patent foramen ovale resulting in closure in the majority of patients. New information was found after bypass in 6% of the patients, resulting in a change in surgery or hemodynamic management in 4% of the total. The most common postbypass finding was valvular dysfunction with repeat bypass in most patients for re-repair or replacement. No major complications occurred. CONCLUSION In adult patients undergoing cardiac surgery, IOTEE provides important important information both before and after bypass that affects surgical and hemodynamic management.

American society of echocardiography and society of cardiovascular anesthesiologists task force guidelines for training in perioperative echocardiography

W hen expertly utilized, perioperative echocardiography can lead to improved outcome in patients requiring cardiovascular surgery and in those suffering perioperative cardiovascular instability. However, prior publications have not specified the requisite training for perioperative echocardiography. Therefore, the American Society of Echocardiography (ASE) and the Society of Cardiovascular Anesthesiologists (SCA) appointed a joint task force to delineate guidelines for training in perioperative echocardiography including the prerequisite medical knowledge and training, echocardiographic knowledge and skills, training components and duration, training environment and supervision, and equivalence requirements for postgraduate physicians already in practice. This document is the result of the task force’s deliberations and recommendations. For the purposes of these guidelines, perioperative echocardiography is defined as transesophageal echocardiography (TEE), epicardial echocardiography, or epiaortic ultrasonography performed in surgical patients immediately before, during, or after surgery. Although transthoracic echocardiography may be indicated and is often performed before and after surgery, it is rarely performed during surgery. Thus, these guidelines do not apply to perioperative transthoracic echocardiography, nor do they apply to TEE performed in nonsurgical patients.